Table 2.
Clinical efficacy measures of the three groups.
| Paramater | MTX group | TGTS group | MTX + TGTS group | |||
|---|---|---|---|---|---|---|
| 0 week | 12 week | 0 week | 12 week | 0 week | 12 week | |
| DAS28 (SD) | 5.91 (1.34) | 4.35 (1.16) | 6.12 (1.23) | 4.24 (1.51) | 6.07 (1.27) | 3.98 (1.28) |
| TJC (SD), n | 14.7 (6.0) | 7.5 (6.3) | 15.3 (7.0) | 7.9 (6.7) | 15.9 (6.1) | 6.6 (5.6) |
| SJC (SD), n | 10.6 (6.5) | 4.2 (5.3) | 10.6 (6.5) | 4.3 (5.1) | 11.4 (7.9) | 3.2 (4.0) |
| CRP (SD), mg/L | 33.3 (28.7) | 14.6 (24.2) | 31.7 (33.2) | 12.1 (20.0) | 38.0 (25.5) | 12.3 (27.1) |
| ESR (SD), mm/h | 54.3 (26.1) | 34.1 (26.3) | 51.7 (24.4) | 32.6 (29.3) | 57.0 (27.2) | 30.2 (19.9) |
| Visual Analogue Score (VAS) evaluated by the patients for pain (SD), mm | 69.0 (18.4) | 44.6 (21.0) | 70.6 (23.4) | 42.2 (19.1) | 71.9 (22.5) | 36.8 (24.2) |
| The patient's global health status assessment of disease (SD), mm | 67.7 (23.7) | 41.4 (27.5) | 65.0 (25.3) | 42.3 (17.8) | 68.4 (19.9) | 34.9 (22.7) |
| The physician's global health status assessment of the patient of disease (SD), mm | 63.2 (22.2) | 38.1 (20.6) | 61.8 (20.2) | 35.9 (25.1) | 64.0 (24.6) | 29.7 (28.3) |
| HAQ (SD) | 1.50 (0.53) | 0.84 (0.92) | 1.74 (0.77) | 0.98 (0.99) | 1.73 (0.60) | 0.90 (0.78) |
Data are presented as mean (SD). DAS28,28-joint count Disease Activity Score; TJC, tender joint count; SJC, swollen joint count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire.